If you ever dreamed of having your brain hooked up to a collection of tubes, pumps, and laboratory gadgets within hours of ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking ...

A clinical trial update wiped out billions in the French company's market cap and raised questions over a potential takeover.

This biotech has a one-of-a-kind colon cancer blood test. Shares broke out of a base on recent news.

Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced ...

A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S ...

In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 ...

This Biotech Stock Is Up 85%. FDA Has Agreed to Review a Skin Cancer Drug. Replimune has twice sought regulatory approval for its experimental melanoma drug, citing an unmet need for advanced ...

The structural advantages that allow China to conduct clinical trials more quickly and at lower costs should be leveraged to ...

Government backing, deep scientific talent and a robust pharma heritage are helping France punch above its weight, but ...